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Aims The SecuraTM ICD and ConsultaTM CRT-D are the ﬁrst deﬁbrillators to have automatic right atrial (RA), right ven-
tricular (RV), and left ventricular (LV) capture management (CM). Complete CM was evaluated in an implantable
cardioverter deﬁbrillator (ICD) population.
Methods
and results
Two prospective clinical studies were conducted in 28 centres in Europe and Israel. Automatic CM data were com-
pared with manual threshold measurements, the CM applicability was determined, and adjustments to pacing outputs
were analysed. In total, 160 patients [age 64.6+10.4 years, 77% male, 80 ICD and 80 cardiac resynchronization
therapy deﬁbrillator (CRT-D)] were included. The differences between automatic and manual measurements
were  0.25 V in 97% (RA CM) and 96% (RV CM) and were all within the safety margin. Fully automatic CM measure-
ments were available within 1 week prior to the 3-month visit in 90% (RA), 99% (RV), and 97% (LV) of the patients.
Results indicated increased output (threshold .2.5 V) due to raised RA threshold in seven (4.4%), high RV threshold
in nine (5.6%), and high LV threshold in three patients (3.8%). All high threshold detections and all automatic modu-
lations of pacing output were adjudicated appropriate.
Conclusion Complete CM adjusts pacing output appropriately, permitting a reduction in ofﬁce visits while it may maximize device
longevity.
The study was registered at ClinicalTrials.gov identiﬁers: NCT00526227 and NCT00526162.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Capture management (CM) is a programmable feature that allows
automatic adjustment of pacing amplitudes in response to changing
pacing thresholds. It monitors whether pacing pulses capture the
myocardium and, optionally, adjusts their amplitude to changing
patient conditions. In CM operation, the device prepares for a
pacing threshold search, conducts the pacing threshold search,
and determines the pacing threshold. Over time, the threshold
measurements are collected to create threshold trends. If CM is
programmed to ‘Adaptive’, the device may automatically adjust
the pacing outputs. If CM is programmed to ‘Monitor’, no adjust-
ments occur. Capture management has been featured in pace-
makers for several years.
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Europace (2010) 12, 811–816
doi:10.1093/europace/euq053The automatic right atrial (RA) and right ventricular (RV) CM
features have been incorporated for the ﬁrst time in high-power
devices (SecuraTM ICD and ConsultaTM CRT-D). The Consulta
CRT-D devices also have the previously validated automatic LV
CM incorporated.
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The algorithms included in Secura ICD and Consulta CRT-D
devices are very similar to those included in recent Medtronic
pacemakers. Automatic threshold measurements occur near
1 a.m. every day and will retry on half-an-hour intervals in the
event of an unsuccessful measurement (e.g. if the intrinsic
rhythm is fast or unstable). The algorithms measure thresholds
based on progressively lowering test pace amplitudes, until loss
of capture is determined. Right atrial CM determines atrial
capture by application of a test pace to the atrium and evaluating
either the response of the intrinsic rhythm or by evaluating the
timing of the conducted ventricular response. Ventricular CM
determines capture by applying a test pace to the RV and evaluat-
ing the timing of the evoked response signal. Left ventricular CM
determines capture by applying a test pace to the LV and compar-
ing the timing of a conducted response in the RV to pre-
determined A–RV and LV–RV conduction characteristics. After
the loss of capture voltage has been determined, the algorithms
conﬁrm capture at the threshold amplitude of 0.125 V above the
loss of capture voltage. When programmed to the Adaptive
mode, pacing output amplitudes are adjusted automatically by
applying the programmed safety margin to the measured threshold.
For RA and RV CM, the safety margin is a multiple of the measured
threshold (nominally, 2.0 for both RA and RV CM). The pacing
output is therefore maintained at a voltage that is larger than the
measured threshold by at least a factor of the safety margin.
Right atrial and RV CM also each have a programmable minimum
adapted amplitude (nominally, 1.5 V and 2.0 V, respectively)
below which pacing output will never be automatically pro-
grammed. Right atrial and RV CM will not adjust pacing outputs
.5 V with a 1.0 ms pulse width. Left ventricular CM uses a differ-
ent safety margin, nominally 1.5 V above the measured threshold.
Left ventricular CM also has a programmable maximum adapted
amplitude such that potential stimulation concerns at high pacing
outputs can be avoided.
There has been a long-standing concern about inappropriate
high measurements based on the original CM algorithm.
2–4
However, more recent generations incorporate features (such as
the ability to switch sensing of the evoked response from bipolar
to unipolar) that have mitigated this problem in pacemakers.
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Capture management will inevitably be increasingly important in
the era of remote follow-up.
1,6–7 As the number of patients with
implantable cardiac devices continues to increase with current
patient demographics, the need to reduce the follow-up burden
increases.
The primary objective of the Secura and Consulta clinical studies
was to evaluate the safety of these devices. A secondary objective
was to evaluate the automated RA and RV CM features in high-
power devices. The LV CM algorithm has already been validated
in a previous CRT-D study
1 and therefore was not validated in
the current clinical study.
In this manuscript, we report on the results of the ﬁrst validation
of the RA and RV CM algorithms in high-power devices, the
applicability of RA, RV, and LV CM, and the effects that RA, RV,
and LV CM features have on pacing outputs.
Methods
Study design
Two separate prospective, multicentre, non-randomized clinical
studies (Secura ICD and Consulta CRT-D) were conducted in
28 centres in Europe and Israel; see Appendix for a list of partici-
pating investigators. Both clinical studies were conducted in com-
pliance with the Declaration of Helsinki, the research protocols
were approved by the local Ethics Committees, and for all patients,
informed consent was obtained prior to enrolment in the study.
The eligibility criteria were primarily designed to reﬂect current
indications for implantable cardioverter deﬁbrillator (ICD)/cardiac
resynchronization therapy deﬁbrillator (CRT-D) implantation.
Inclusion criteria
Patients with an established indication for ICD or CRT-D implan-
tation according to international guidelines,
8–9 or elective device
replacement; who were receiving optimal medical therapy, and
were geographically stable and available for follow-up. In addition
for the Consulta study, patients receiving new implants who
were in NYHA class III or IV and had intrinsic QRS duration
.120 ms within 30 days prior to baseline; and LV ejection fraction
(LVEF)  35% within 180 days prior to baseline (patients under-
going CRT-D unit replacement were assumed to have met these
criteria at the time of original implant). Local Ethics Committee
approval and written informed consent were obtained in all cases.
Exclusion criteria
Patients with a life expectancy less than the duration of the study;
with medical conditions precluding the testing required by the
study protocol or otherwise limiting study participation (including
pregnancy and breastfeeding); with mechanical tricuspid heart
valves; participating in any concurrent device study, or any drug
study that might confound the results of this trial; in need of
device replacement with lead integrity problems (and the lead(s)
can or will not be replaced).
Manual threshold measurements were obtained at the 1-month
follow-up and the automatic RA and RV CM data were compared
with manual threshold measurements for all implanted subjects
with a valid manual threshold test and a successful CM threshold
measurement completed  2 days beforehand. The thresholds
were determined by decreasing the amplitude in steps of 0.125 V
(automatic) and 0.25 V (manual), respectively.
The CM algorithms were programmed to measure the
threshold once per day. Applicability was deﬁned as the percen-
tage of patients who had successful threshold measurement over
a given time period prior to the 3-month visit. Applicability was
examined based on the data of the 3-month visit in subjects with
device programming that allowed automatic threshold measure-
ments. The 3-month follow-up was chosen for analysis because
the maximum number of patients had device data for this
period. Although CM applicability may be higher with more fre-
quent measurement attempts,
10 a daily measurement was chosen
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excessive measurement attempts. The CM applicability was deter-
mined for the following periods: 1, 3 days, 1 week, 1, and 3 months
prior to the 3-month follow-up.
At the 6-month follow-up visit, automatic threshold data were
analysed in patients with devices programmed to the Adaptive
CM mode (RA, RV, and LV CM), to determine how often and in
which direction the current CM algorithms adjusted the pacing
outputs since the pre-discharge visit. The 6-month follow-up was
chosen for this analysis to ensure that the leads had matured
past the acute implant phase and that the CM algorithms had
time to adjust the pacing outputs.
Statistical analysis
Descriptive statistics were performed to summarize the results of
these analyses.
Data from the comparison between the manual threshold
results and the automatic CM threshold results are presented as
n, mean, standard deviation (SD), median, range, and 95% conﬁ-
dence interval. Capture management applicability is presented as
absolute numbers. Data from the adjustment of the pacing
output are represented as n, mean, SD, range, and percentages.
Results
Patient demographics
In total, 160 patients were successfully implanted and included in
the two clinical studies. Those 160 patients had a mean age of
64.6+10.4 years, 77% were male, mean LVEF was 27.6+9.6%,
80 were ICD, and 80 were CRT-D patients. Of the 160 patients,
42 (26%) had atrial ﬁbrillation (AF) at baseline with 24 paroxysmal
AF, 9 persistent AF, and 9 permanent AF. The CRT-D and the ICD
patient groups had similar demographics and device threshold data
(Table 1).
Manual vs. automatic capture
management
Table 2 details 1-month paired (manual and CM) data that were
available for 159 patients including 114 paired atrial measurements
and 139 paired RV measurements. The combined results showed
that for RA and RV CM, respectively, 86 and 84% of automatic
measurements were within 0.125 V of the manual measurement,
97 and 96% were within 0.25 V of the manual measurement, and
100 and 99.3% were within 0.5 V. All differences were well
within the standard two-fold safety margin for output automatically
set by the device (Figures 1 and 2).
Capture management algorithm
applicability
The CM applicability was measured at 1, 3 days, 1 week, 1, and
3 months prior to the 3-months follow-up visit. Right atrial CM
applicability was 119 of 135 (88%), 122 of 135 (90%), 122 of
135 (90%), 122 of 135 (90%), and 125 of 134 (93%) when
measured within 1, 3 days, 1 week, 1, and 3 months, respectively.
The RV CM applicability was 141 of 144 (98%), 142 of 144 (99%),
142 of 144 (99%), 142 of 144 (99%), and 143 of 144 (99%) when
measured within 1, 3 days, 1 week, 1, and 3 months, respectively.
The LV CM applicability was 62 of 68 (91%), 62 of 68 (91%), 66 of
68 (97%), 66 of 68 (97%), and 66 of 68 (97%) when measured
within 1, 3 days, 1 week, 1, and 3 months, respectively. Of the
16 patients without an atrial threshold measurement within 1
day, 8 were due to persistent atrial tachycardia/AF, 5 were due
to signiﬁcant pacemaker dependence (i.e. nearly 100% atrial and
ventricular paced), and 3 were due to high or variable rates. The
lack of RV and LV measurements were due to a competing
rhythm. Competing rhythms can occur due to high or variable
intrinsic rate or short AV. These results are consistent with pre-
vious studies in pacemaker
5 and CRT-D patients.
The RA and RV CM algorithms indicate a ‘high threshold’ when
the measured threshold is .2.5 V. In these cases, when pro-
grammed to the Adaptive mode, the algorithm adjusts pacing
output to 5 V with a 1.0 ms pulse width. The CM results based
on 160 patients indicated high RA threshold in seven patients
(4.4%) and high RV threshold in nine patients (5.6%). Because LV
thresholds tend to be higher than A and RV thresholds, the LV
CM algorithm will measure thresholds up to 6.0 V. The LV CM
results based on 80 patients indicated that the algorithm was
unable to maintain the programmed safety margin due to high
thresholds in three patients (3.8%) at some point prior to the
6-month follow-up.
All of these indications of high thresholds were due to appropri-
ate measurement of high thresholds (ﬁve patients), lead dislodge-
ments (four patients), acute effects of lead maturation (six
patients), or incomplete connection of the lead in the header
block (one patient).
Pacing output
Right atrial, RV, and LV CM were programmed to the Adaptive
mode with 6 months of follow-up data in 133, 132, and 51
devices, respectively. The CM adapted pacing outputs were com-
pared with the clinician programmed pre-discharge pacing
Table 1 Patient demographics
Number of subjects 160
Age (years), mean (SD) 64.6+10.4
Male 123 (77%)
Myocardial infarction 90 (56%)
Atrial ﬁbrillation 42 (26%)
Paroxysmal AF 24
Persistent AF 9
Permanent AF 9
NYHA class II 30 (19%)
NYHA class III 113 (71%)
NYHA class I, IV 8 (5%)
Beta-blocker 139 (87%)
ACE-inhibitor 140 (88%)
Diuretics 124 (78%)
No heart failure 6 (4%)
LVEF (%), mean (SD) 27.6+9.6
Ischaemic cardiomyopathy 90 (56%)
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was the pacemaker nominal setting). Capture management
increased the RA output in four patients (3.0%), increased the
RV output in nine patients (6.8%), and increased the LV output
in one patient (2.0%). The maximum output increase in each
chamber was 1.5 V. Capture management decreased the RA
output in 112 patients (84.2%), decreased the RV output in 115
patients (87.1%), and decreased the LV output in 49 patients
(94.2%). For ICD subjects, the mean decreases in RA and RV
were 1.7 and 1.1 V, respectively. For CRT-D subjects, the mean
decreases in RA, RV, and LV were 1.2, 1.2, and 1.4 V, respectively.
Overall, the output decreased .1 V in each chamber: the mean
decreases in RA, RV, and LV were 1.5, 1.2, and 1.4 V, respectively
(Table 3). All adjustments were found to be appropriate when CM
and manual threshold measurements were examined.
Discussion
This study demonstrates that the CM algorithms perform as
intended, reducing or increasing pacing outputs where appropriate
without compromising the safety margin. The CM algorithms
adjust the RA, RV, and LV pacing outputs appropriately and only
in response to true changes in the patients’ pacing thresholds.
The inappropriate adjustments to high pacing outputs that were
occasionally observed in earlier pacemakers were not observed
in this study. All of the indications of high output were due to
appropriate measurement of high threshold caused by chronic
high thresholds, lead dislodgements, acute effects of lead matu-
ration, or incomplete connection of the lead in the header block.
The differences that were seen between CM threshold data and
manual threshold data in this study may be explained by:
...............................................................................................................................................................................
Table 2 Automatic threshold measurements (CM) vs. manually determined threshold
Automatic threshold Manual threshold Difference, CM 2 manual
RA threshold (n ¼ 114)
Mean+SD 0.713+0.242 0.730+0.231 20.018+0.141
Median 0.625 0.750 0.000
Range 0.250–1.625 0.250–1.500 20.500–0.375
95% CI 0.668, 0.758 0.687, 0.773 20.044, 0.009
RV threshold (n ¼ 139)
Mean+SD 0.843+0.430 0.885+0.425 20.042+0.147
Median 0.750 0.750 0
Range 0.375–2.500 0.250–2.250 20.500–0.625
95% CI 0.771, 0.915 0.814, 0.956 20.067, 20.018
Figure 1 Overall distribution of difference in atrial thresholds
obtained by RA CM and manual testing (1-month data).
Figure 2 Overall distribution of difference in RV threshold
obtained by RV CM and manual testing (1-month data).
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typically quite low, because the measurements were taken at
different points in time, there is some normal variation that
can occur.
7,10
(ii) Manual thresholds are performed using 0.25 V threshold steps,
whereas the automatic thresholds use 0.125 V steps. When all
other variables are equal, this difference in step size will result
in manually measured thresholds that are on average slightly
larger than automatically measured thresholds. This accounts
for the slight left shift in the data presented in Figures 1 and 2.
The CM features in the Consulta CRT-D and the Secura ICD
provide daily conﬁrmation of pacing capture and appropriate main-
tenance of patients’ safety margins while avoiding adverse effects.
The adjustments to pacing outputs can maximize battery longevity
in patients who require pacing. In addition, cost-effectiveness may
increase as the number of clinic visits reduces, and the time
required for follow-up visits may decrease. At the same time,
reliable CM allows for an increase in the number of remote
device follow-ups, which may add to cost-effectiveness.
11–18
Conclusion
This study demonstrates that the RA and RV CM algorithms per-
formed as intended. The CM algorithms adjust the RA, RV, and LV
pacing outputs appropriately and only in response to changes in
the patients’ pacing thresholds. Complete CM reliably and safely
manages pacing outputs, may reduce the number of routine
in-ofﬁce visits, and may maximize battery life.
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